Search the Video Library

Filter by Date

Video Language

Filter by Cancer Type:

Displaying Results 31 - 37 of 37

Blood Cancers Video Library: CLL and Non Hodgkin Lymphoma: Should all Hodgkin’s Lymphoma patients be treated the same?

GRACE joined a number of top faculty in the area of hematology in Whistler BC, for the 3rd Annual Summit on Hematologic Malignancies. John Kuruvilla, MD, Associate Professor, Princess Margaret Hospital, University Health Network in Toronto, Canada, spoke with GRACE about Chronic Lymphocytic Leukemia

Blood Cancers Video Library: Are Vaccines Dead in Lymphoma and CLL?

GRACE joined a number of top faculty in the area of hematology in Whistler BC, for the 3rd Annual Summit on Hematologic Malignancies. Joshua Brody, MD, Oncologist and Director, Assistant Professor of Medicine, Hematology & Medical Oncology at Mount Sinai Hospital spoke with GRACE about the question

Blood Cancers Video Library: FCR vs BR – Is One Better?

GRACE joined a number of top faculty in the area of hematology in Whistler BC, for the 3rd Annual Summit on Hematologic Malignancies. Jennifer Brown, MD, PhD, Director of the CLL Center at the Dana-Farber Cancer Institute spoke with GRACE and provided a provoking and educational discussion on FCR vs

Blood Cancer Video Library - What Is The Significance Of IGHV Mutations And How Are They Assessed?

We recently joined a number of top faculty in the area of hematology in Whistler BC, for the 3rd Annual Summit on Hematologic Malignancies. Jennifer Brown, MD, PhD, Director of the CLL Center at the Dana-Farber Cancer Institute spoke with GRACE and provided provoking and educational discussions on

Elderly Patients: Single Agent vs. Doublet Chemotherapy

Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, discusses the use of single agent vs. doublet chemotherapy in elderly patients.

Management of Locally Advanced NSCLC in the Elderly and Frail

Dr. Mark Socinski, University of Pittsburgh Medical Center, describes strategies for treatment of the elderly and frail patient with locally advanced NSCLC.

Spanish Blood Cancer Library - What are the risks and benefits of Ibrutinib and Idelalisib? How do you manage the side effects of the new kinase inhibitors?
¿Cuáles son los riesgos y beneficios de ibrutinib y de idelalisib? ¿Cómo manejamos los efectos secundarios de los nuevos inhibidores de la tirosina cinasa?

GRACE sat down with Dr. Marco Ruiz to discuss "What are the risks and benefits of Ibrutinib and Idelalisib?" for our continuing video series with our Spanish speaking faculty on updates in blood cancer treatments.